-
Phenothiazines, ROS, and Autophagy in Macrophages
2026-09-15
The 2025 Frontiers in Immunology study shows that phenothiazines can strengthen macrophage antibacterial activity through coordinated lysosomal activation, autophagy, and reactive oxygen species accumulation. Its host-directed therapy framework offers a mechanistic basis for studying intracellular bacterial control without relying solely on direct antibiotic action.
-
Nintedanib (BIBF 1120): Mechanism and Research
2026-09-15
Nintedanib, also called BIBF 1120, is an orally active triple angiokinase inhibitor that blocks VEGFR, FGFR, and PDGFR signaling. Its strongest research rationale is pathway-level angiogenesis inhibition, while ATRX-deficient glioma findings support biomarker-aware RTK and PDGFR studies rather than a proven glioma indication.
-
JSH-23: A Practical NF-κB Inhibitor Workflow
2026-09-14
JSH-23 is a mechanistic NF-κB inhibitor for separating p65 transcriptional activity from upstream IκB degradation. This guide shows how to apply it in macrophage inflammation research, cytokine assays, inflammasome studies, and a cisplatin-induced acute kidney injury model while avoiding common interpretation errors.
-
Trametinib (GSK1120212) Experimental Workflows
2026-09-14
Trametinib (GSK1120212) is more than a viability reagent: it connects MEK1/2 target engagement with cell-cycle, apoptosis, and chromatin-level readouts. This workflow shows how to use it in cancer models and human pluripotent stem cells while reducing common dosing, solubility, and interpretation errors.
-
(-)-JQ1: Inactive Control for BET Assays
2026-09-13
(-)-JQ1 is a matched stereoisomeric control for separating BET-dependent biology from vehicle effects, cytotoxic stress, and assay artifacts. This workflow shows how to deploy it in epigenetics research, BRD4-dependent cell line studies, and pancreatic cancer screening models.
-
MK-5108 (VX-689) Assay Workflows
2026-09-12
MK-5108 (VX-689) enables selective Aurora A inhibition across biochemical, cell-based, and translational oncology workflows. This practical guide connects retinoblastoma evidence with dose-response design, cell cycle readouts, xenograft interpretation, and troubleshooting for reproducible cancer research.
-
SGI-1027 DNA Methyltransferase Inhibitor Workflows
2026-09-12
SGI-1027 combines direct DNA methyltransferase inhibition with DNMT1 protein depletion, making it useful for connecting CpG methylation changes to tumor suppressor gene reactivation. A response workflow that separates growth arrest from cell killing can reveal effects that a single endpoint viability assay may miss.
-
Nintedanib: ATRX-Aware Assay Design
2026-09-11
Nintedanib (BIBF 1120) is a triple angiokinase inhibitor whose VEGFR, FGFR, and PDGFR activity supports genotype-aware cancer assays. This article translates ATRX-deficient glioma findings into practical experimental decisions while distinguishing vascular, tumor-cell, and antifibrotic readouts.
-
HyperScribe T7 High Yield RNA Synthesis Kit
2026-09-11
The HyperScribe T7 High Yield RNA Synthesis Kit supports T7 RNA polymerase transcription for high-yield in vitro RNA production. Its documented workflow supports standard, capped, labeled, biotinylated, and modified-nucleotide RNA research applications, while transcript quality and modification performance require application-specific validation.
-
TMEM16F, Lipid Scrambling, and Ferroptosis
2026-09-10
Yang et al. identify TMEM16F-mediated phospholipid scrambling as a late-stage suppressor of ferroptosis that protects the plasma membrane from catastrophic failure. The study further shows that disabling this membrane-repair axis can slow tumor growth and cooperate with PD-1 blockade, linking ferroptotic membrane damage to antitumor immunity.
-
SGI-1027 DNA Methyltransferase Inhibitor Workflow
2026-09-10
Build a more informative SGI-1027 workflow by separating growth inhibition from cell killing and pairing viability with methylation, DNMT1, and gene-reactivation readouts. This practical guide covers assay setup, dose and time optimization, troubleshooting, and combination-study design for cancer epigenetics research.
-
Nintedanib: Angiokinase Biology Meets ATRX Strategy
2026-09-09
Nintedanib (BIBF 1120) offers a translational framework for connecting VEGFR, FGFR, and PDGFR biology with ATRX-informed cancer research. This article integrates mechanism, assay strategy, biomarker logic, and fibrosis relevance without overstating the current evidence.
-
1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine Control
2026-09-09
PP 3 is a practical negative-control reagent for separating PP 2-specific effects from vehicle, scaffold, and pathway artifacts in Src kinase signaling pathway research. This workflow connects matched chemical controls with vascular contraction, ROS, and L-type calcium-channel assays highlighted by a recent rat artery study.
-
Nintedanib (BIBF 1120) in ATRX-Stratified Glioma
2026-09-08
Use Nintedanib (BIBF 1120) to interrogate coordinated VEGFR, FGFR, and PDGFR blockade in genotype-defined cancer models. This workflow combines ATRX stratification, apoptosis profiling, and temozolomide combination testing while addressing formulation and exposure challenges.
-
PD0325901: MEK Inhibition for Cancer Research
2026-09-07
PD0325901 is a selective MEK inhibitor that suppresses ERK phosphorylation and produces cell-cycle and apoptosis-associated phenotypes in cancer models. Product-reported xenograft findings support its use as a research tool for studying RAS/RAF/MEK/ERK signaling pathway inhibition, not as a diagnostic or medical treatment.